14:15 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The U.S. Food and Drug Administration approved Lilly's Kisunla once-monthly infusion as a treatment for Alzheimer's disease in adults with early symptomatic disease, including those with mild cognitive impairment as well as some forms of mild dementia. The pharmaceutical giant said Kisunla slowed cognitive and functional decline by up to 35% versus placebo at 18 months in its phase 3 study and reduced participants' risk of progressing to the next clinical stage of disease by up to 39%. Kisunla will cost about $12,522 for six months of treatment, Lilly said. Dow Jones & Co. owns Factiva. (jennifer.tershak@wsj.com)


(END) Dow Jones Newswires

07-02-24 1430ET